Jefferies analyst Raj Denhoy raised his price target for Wright Medical to $30 from $28 and says the stock remains a top pick at his firm. At $660M and growing in the high single digits, the shoulder replacement market is one of the more attractive orthopedic segments, Denhoy tells investors in a research note. He believes Wright is positioned to benefit from the growth. The analyst points out that his firm's survey of 50 orthopedic surgeons suggests that short-stem, bone-sparing implants will take market share, and that Wright's Simpliciti remains the only such offering approved in the U.S. Denhoy keeps a Buy rating on Wright Medical.